Systemic Lupus Erythematosus
GPTKB entity
Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
autoimmune disease
|
| gptkbp:abbreviation |
SLE
|
| gptkbp:affects |
multiple organ systems
|
| gptkbp:associatedWith |
anti-dsDNA antibodies
complement deficiency antinuclear antibodies anti-Smith antibodies |
| gptkbp:cause |
unknown
|
| gptkbp:complication |
gptkb:anemia
neurological disorders pericarditis thrombocytopenia pleuritis lupus nephritis |
| gptkbp:diagnosedBy |
gptkb:ANA_test
gptkb:anti-dsDNA_antibody_test clinical criteria |
| gptkbp:field |
immunology
internal medicine dermatology nephrology rheumatology |
| gptkbp:firstDescribed |
gptkb:Charles_Louis_Alphonse_Laveran
1872 |
| https://www.w3.org/2000/01/rdf-schema#label |
Systemic Lupus Erythematosus
|
| gptkbp:ICD-10_code |
gptkb:M32
|
| gptkbp:onset |
usually between ages 15 and 45
|
| gptkbp:prevalence |
more common in women
more common in African Americans more common in Asians more common in Hispanics |
| gptkbp:riskFactor |
genetic predisposition
female sex hormonal factors environmental triggers |
| gptkbp:symptom |
gptkb:antinuclear_antibody
fever fatigue arthritis joint pain hair loss photosensitivity skin rash hematologic disorder oral ulcers serositis discoid rash immunologic disorder malar rash renal disorder |
| gptkbp:treatment |
gptkb:NSAIDs
biologics corticosteroids immunosuppressants antimalarials |
| gptkbp:bfsParent |
gptkb:Lupus_Erythematosus_Systemicus
gptkb:Lupus_Erythematosus |
| gptkbp:bfsLayer |
7
|